Skip to content

A Clinical Comparison of Modified Erandamoola Niruha Basti and Kshara Basti for reducing Inflammation in patients with Rheumatoid Arthritis

A Comparative Clinical Study to Evaluate the Efficacy of Modified Erandamoola Niruha Basti and Kshara Basti on Inflammatory markers in Rheumatoid Arthritis - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/101887
Enrollment
30
Registered
2026-01-23
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M069- Rheumatoid arthritis, unspecified

Interventions

None listed

Sponsors

Dr Sushma S Bhat
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients presenting with one or more signs and symptoms of Rheumatoid Arthritis. 2) Patients irrespective of gender within the age group of 20 years to 60 years. 3) Patients with complaints of multiple joint pain less than or equal to 5 years. 4) Sero-positive and Sero-negative Rheumatoid Arthritis. 5) Freshly diagnosed patients of Rheumatoid Arthritis. 6) Patients who are Yogya for Basti. 7) Patients who are voluntarily willing to sign informed consent.

Exclusion criteria

Exclusion criteria: 1) Congenital deformities of the joints. 2) Patients suffering from major illnesses like HIV, Tuberculosis, Syphilis, malignancy etc. 3) Patients having fracture and joint deformities. 4) Any major systemic illness which interferes with the line of treatment. 5) Pregnancy and Lactating women. 6) Anasthapya are excluded. 7) Patients on DMARD (Disease Modifying Anti Rheumatic Drugs) therapies.

Design outcomes

Primary

MeasureTime frame
Assessment of change in the Inflammatory markers of Rheumatoid Arthritis mentioned under Objective parameters.Timepoint: 1st Assessment on 0th day (Before treatment). 2nd Assessment on 9th day (After treatment). Follow up on 24th day.

Secondary

MeasureTime frame
Improving the Quality of life related to Rheumatoid Arthritis.Timepoint: 1st Assessment on 0th day (Before treatment). 2nd Assessment on 9th day (After treatment). Follow up on 24th day.

Countries

India

Contacts

Public ContactDr Arun B Jainer

SDM Institute of Ayurveda and Hospital, Anchepalya

draruns@gmail.com9900940333

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026